Comments on: Monday Deal Review: February 16, 2009 http://crossborderbiotech.ca/2009/02/16/monday-deal-review-february-16-2009/ Biotechnology, Health and Business in Canada, the United States and Worldwide Mon, 02 Apr 2012 12:31:04 +0000 hourly 1 http://wordpress.com/ By: Monday Deal Review: June 29, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/16/monday-deal-review-february-16-2009/comment-page-1/#comment-564 Tue, 30 Jun 2009 02:22:17 +0000 http://crossborderbiotech.ca/?p=536#comment-564 [...] Inc. (TSX-V: GAP), no novice when it comes to debt-for-shares deals, announced that it is converting $215,201 owed to the National Research Council of Canada, [...]

]]> By: Monday Deal Review: March 2, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/16/monday-deal-review-february-16-2009/comment-page-1/#comment-96 Mon, 02 Mar 2009 12:07:52 +0000 http://crossborderbiotech.ca/?p=536#comment-96 [...] Inc.(TSX-V: GAP) announced that the conversion of debentures by SC Stormont Holdings Inc. first announced February 11 has been completed.  Following conversion, there are 77,079,124 common shares outstanding, of [...]

]]> By: Monday Deal Review: February 23, 2009 « The Cross-Border Biotech Blog http://crossborderbiotech.ca/2009/02/16/monday-deal-review-february-16-2009/comment-page-1/#comment-70 Mon, 23 Feb 2009 12:10:40 +0000 http://crossborderbiotech.ca/?p=536#comment-70 [...] Therapeutics Inc. (TSX-V: ICO), which raised $1.3 million last week, announced that it granted 100,000 stock options to select Directors of the Company who have not [...]

]]>